This risk minimisation material is a condition of the marketing authorisation. This Checklist supports the communication of critical tasks and actions throughout the patient’s cycle of treatment with mavacamten; before starting treatment, during treatment, and after treatment has been discontinued.

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Please ensure that you carry this card with you at all times.

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Embryo-fetal toxicity risk information is presented as a tear-out in the Patient Guide, which can be removed if the risk of embryo-fetal toxicity does not apply.